Fibroblast Growth Factor
Elevated levels of fibroblast growth factor 23 may be linked with heart failure risk
Elevated levels of fibroblast growth factor 23 may be associated with an increased risk for heart failure in adults with chronic kidney disease, according to a recently published study.
Pegozafermin lowers high triglycerides, non-HDL and ApoB vs. placebo in small trial
Pegozafermin, a fibroblast growth factor 21 analog, reduced atherogenic particles in patients with severe hypertriglyceridemia and improved liver fat and insulin resistance compared with placebo, a speaker reported.
VIDEO: Positive results seen with engineered fibroblast growth factor for Fuchs’
CHICAGO — In this Healio Video Perspective from the AAO meeting, Francis W. Price Jr., MD, discusses an engineered fibroblast growth factor from Trefoil Therapeutics for Fuchs’ endothelial corneal dystrophy.
FDA approves pemigatinib for myeloid/lymphoid neoplasms with FGFR1 rearrangement
The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and rearrangement of fibroblast growth factor receptor 1, according to a press release from the agent’s manufacturer.
Burosumab effects persist long-term for children with rare form of rickets
Treatment with the monoclonal antibody burosumab led to normalized serum phosphorus levels and improvements in rickets severity and lower-limb deformity among young children with X-linked hypophosphatemia, according to a speaker.
NASH resolves, fibrosis improves in 22% treated with growth factor analogue
Fibroblast growth factor 19 analogue aldafermin showed dose- and duration-dependent reduction in liver fat with resolution of non-alcoholic steatohepatitis in more than one-fifth of cases, according to a presenter at the Digital International Liver Congress.
FDA approves burosumab for tumor-induced osteomalacia
The FDA approved burosumab-twza injection to treat patients aged 2 years and older with tumor-induced osteomalacia, according to an agency press release.
Burosumab improves bone healing, quality of life in tumor-induced osteomalacia
A small cohort of adults with tumor-induced osteomalacia experienced improvements in phosphate and skeletal metabolism, physical functioning and quality of life after 144 weeks of treatment with burosumab therapy, study data show.
Combination therapy trial for locally advanced, metastatic HCC underway
Researchers uncover ‘novel drug target for glioblastoma’
An international study of glioblastoma revealed a cellular pathway that appears to contribute to glioma stem cell spread and proliferation.